Shopping Cart
- Remove All
- Your shopping cart is currently empty
Bisindolylmaleimide VIII (Ro-31-7549) is a selective and potent protein kinase C (PKC) inhibitor with good inhibition of PKC-α, PKC-β I, PKC-β II, PKC-γ, and PKC-ε.Bisindolylmaleimide VIII Bisindolylmaleimide VIII inhibits T cell-mediated autoimmune diseases and enhances Fas-mediated apoptosis through a protein kinase C-independent mechanism.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $293 | In Stock | |
5 mg | $722 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,520 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Bisindolylmaleimide VIII (Ro-31-7549) is a selective and potent protein kinase C (PKC) inhibitor with good inhibition of PKC-α, PKC-β I, PKC-β II, PKC-γ, and PKC-ε.Bisindolylmaleimide VIII Bisindolylmaleimide VIII inhibits T cell-mediated autoimmune diseases and enhances Fas-mediated apoptosis through a protein kinase C-independent mechanism. |
Targets&IC50 | PKC (rat brain):158 nM, PKCβI:195 nM, PKCγ:213 nM, PKCε:175 nM, PKCβII:163 nM, PKCα:53 nM |
In vitro | Ro-31-7549 (5 μM; 8, 12h; 1321N1 cells) significantly increases TRA-8-induced cell death in a time- and dose-dependent manner.[2] After combined treatment with Ro-31-7549 (5 μM; 6h; 1321N1 cells) and TRA-8, procaspase-8 was significantly reduced at 4 h and completely disappeared at 6h.[2] |
In vivo | Ro-31-7549 (100 μg; i.p.; every other day for three doses; 6-8-week-old female NOD/SCID mice) combined with toTRA-8, resulted in nearly complete tumor regression. Bisindolylmaleimide VIII alone did not result in significant tumor regression.[2] |
Alias | RO 318161, Ro 31-7549, Bis VIII |
Molecular Weight | 398.46 |
Formula | C24H22N4O2 |
Cas No. | 125313-65-7 |
Smiles | O=C1NC(=O)C(C2=CN(C=3C=CC=CC23)CCCN)=C1C4=CN(C=5C=CC=CC45)C |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.